- Sensu Investor
- Posts
- Lupin Ltd
Lupin Ltd
July 12, 2024
FOLLOW-UP
September 27, 2024 | Total Return: +23.78%
ORIGINAL ARTICLE
FREE & PREMIUM
Lupin Ltd
Ticker: LUPIN.NSE
Addition to:
✅ SENSU Watchlist [INDIA]
Addition Date: July 12, 2024
Price per Share: 1797.75 INR
TABLE OF CONTENTS
THE COMPANY
In the bustling city of Mumbai in 1968, a chemistry professor named Desh Bandhu Gupta had a vision - to create affordable medicines that could improve the lives of millions. With just 5,000 rupees borrowed from his wife, Gupta laid the foundation for what would become one of India's largest pharmaceutical companies: Lupin Ltd.
Lupin's journey began with a focus on producing essential vitamins and minerals for India's mother and child health programs. However, it was the company's entry into tuberculosis (TB) treatments that truly set it apart. Recognizing the devastating impact of TB in India, Lupin became a pioneer in manufacturing affordable anti-TB drugs. This move not only addressed a critical health need but also established Lupin as a socially responsible pharmaceutical company.
As Lupin grew, so did its ambitions. The company expanded its product portfolio beyond TB treatments, venturing into areas like cardiovascular health, diabetes, and respiratory diseases. But what truly catapulted Lupin onto the global stage was its foray into the generics market.
Lupin's business model revolves around developing and manufacturing high-quality generic versions of branded drugs once their patents expire. This approach allows the company to offer essential medicines at a fraction of the cost of branded alternatives, making healthcare more accessible to millions worldwide.
The company's success in the generics space is built on a foundation of robust research and development. Lupin invests heavily in its R&D capabilities, with state-of-the-art facilities staffed by hundreds of scientists. This commitment to innovation has enabled the company to develop complex generics and even venture into biosimilars – generic versions of biologic drugs.
Lupin's growth story isn't limited to India. The company has strategically expanded its presence across the globe through a combination of organic growth and smart acquisitions. Today, Lupin has a significant footprint in key markets like the United States, Europe, Japan, and South Africa.
In the U.S., which accounts for a substantial portion of Lupin's revenue, the company has established itself as a trusted provider of generic drugs. Its acquisition of Gavis Pharmaceuticals in 2015 further strengthened its position in the world's largest pharmaceutical market.
While generics remain at the core of Lupin's business, the company has been diversifying its offerings. It has made strides in developing novel drug delivery systems and is exploring opportunities in biotechnology. Lupin has also entered the over-the-counter (OTC) market with products like nutritional supplements and skincare items.
STOCK PRICE
The dynamic background color reflects overall market valuation, allowing you to quickly assess both stock-specific trends and market conditions at a glance.
Why logarithmic? It displays percentage changes uniformly, making price movements easily comparable across different ranges. A 100% increase appears the same whether from $10 to $20 or $100 to $200.
MANAGEMENT ANALYSIS
Vinita Gupta, the dynamic CEO of Lupin Ltd., has been a driving force behind the company's global expansion and success. Born into a pharmaceutical family, Vinita grew up witnessing her father, Desh Bandhu Gupta, build Lupin from the ground up. This early exposure to the industry shaped her passion for healthcare and business acumen.
After earning her pharmacy degree from the University of Mumbai and an MBA from the Kellogg School of Management, Vinita joined Lupin in 1993. She quickly rose through the ranks, showcasing her strategic vision and leadership skills. In 2013, she became the CEO, making her one of the few women to lead a major pharmaceutical company.
Vinita's leadership style is characterized by a blend of innovation, calculated risk-taking, and a strong focus on patient needs. Under her guidance, Lupin has expanded its global footprint, particularly in the U.S. market, where it now ranks as the third-largest generics company by prescriptions.
One of Vinita's most notable achievements was spearheading Lupin's acquisition of Gavis Pharmaceuticals in 2015, the largest acquisition in the company's history at $880 million. This bold move significantly boosted Lupin's presence in the U.S. market and expanded its product portfolio.
An interesting fact about Vinita is that despite her busy schedule, she makes time to mentor young women in the pharmaceutical industry, believing in the importance of fostering the next generation of leaders. Her commitment to both business excellence and social responsibility has earned her numerous accolades, including being named in Forbes' "Asia's 50 Power Businesswomen" list multiple times.
Employee Sentiment
Many employees praise Lupin for its good work culture, supportive environment, and opportunities for learning and growth. The company is often described as having a friendly atmosphere with approachable leadership. Employees appreciate the work-life balance, good benefits, and competitive salaries. The company is seen as providing valuable experience, especially for those early in their careers. Many reviewers mention that Lupin offers good training programs and chances for career development. The company's focus on quality and ethics in pharmaceutical manufacturing is also highlighted as a positive by several employees.
A common complaint is about work pressure and long hours, especially in certain departments. Some employees feel there is a lack of work-life balance. There are mentions of office politics and favoritism affecting career growth opportunities. Several reviews point to issues with middle management, citing poor communication and decision-making. Some employees feel that salaries and increments are not competitive enough compared to industry standards. There are also concerns about job security, with some mentioning unexpected layoffs. A few reviews indicate dissatisfaction with the company's handling of employee feedback and grievances.
"Pros: High growth, salary, benefits, bonus, visibility through the entire leadership team, and ability to communicate and influence all levels. Cons: Traditional leadership with old school mentality, not expanding headcount, very conservative in spending, no remote work."
"CEO Vinita Gupta is a really strong leader. There are a few good leaders in the company but they are getting harder to find as good people are being fired and replaced by under qualified cronies."
FINANCIAL ANALYSIS
⭐⭐⭐ Quality Score | ⭐⭐⭐ Value Score | ⭐⭐⭐⭐⭐ Growth Score |
Lupin's Return on Invested Incremental Capital (ROIIC) shows a remarkable turnaround in recent years. While the 10-year and 5-year ROIIC figures are low or negative, indicating past struggles with capital efficiency, the 3-year ROIIC of 187.78% reveals a dramatic improvement. This suggests Lupin has significantly enhanced its ability to generate returns from new investments in the short term. The company's ranking among peers has also improved substantially, rising from the 14th percentile over 5 years to the 93rd percentile over 3 years. This turnaround aligns with Lupin's strategic focus on complex generics and operational efficiencies.
10-Years | 5-Years | 3-Years | |
|---|---|---|---|
ROIIC | 3.96% | -38.66% | 187.78% |
Ranking | 51.71% | 14.72% | 93.29% |
Lupin Ltd's earnings yield has shown significant volatility over the past 7 years, reflecting the company's changing profitability. After a low of -4.5% in 2021, likely due to pandemic impacts, the yield rebounded strongly to 2.59% in 2023, indicating improved financial performance. This recent positive trend suggests Lupin has successfully navigated challenges and enhanced its earnings potential. The fluctuations highlight the dynamic nature of the pharmaceutical industry and Lupin's resilience in adapting to market conditions. The current trailing twelve-month yield of 2.14% shows continued stability.
Earnings Yield
Lupin Ltd has shown a fluctuating trend in its price-to-book (PTB) ratio over the past seven years, reflecting changing investor sentiment and company performance. The ratio hit a low in 2019 but has since rebounded strongly, reaching its highest point in the trailing twelve months (TTM). This recent surge suggests growing investor confidence in Lupin's future prospects.
Price-to-Book Ratio
MOST SIGNIFICANT MOATS
Lupin has built a strong brand name and reputation for quality over its decades-long history. This is perhaps its most valuable moat. In the pharmaceutical industry, doctors and patients place a high premium on trusted brands, especially for critical medications. Lupin's established brand allows it to charge premium prices and maintain customer loyalty, even in the face of competition from generics. This brand equity is difficult for new entrants to replicate quickly.
Lupin has secured regulatory approvals in multiple countries and has a strong track record of compliance with strict quality standards. Getting new drugs and manufacturing facilities approved by regulators like the US FDA is a long, expensive process. Lupin's existing approvals and compliance systems give it a major advantage over potential new competitors who would need years to reach the same level.
As one of the largest pharmaceutical companies globally, Lupin benefits from economies of scale in manufacturing. Its large, efficient production facilities allow it to produce drugs at a lower per-unit cost than smaller competitors. This cost advantage is difficult for new or smaller players to match without massive capital investments.
MOST SIGNIFICANT RISKS
Risk: Increased scrutiny from regulatory agencies like the FDA and potential non-compliance issues.
Impact: Could lead to product recalls, manufacturing shutdowns, or fines, severely impacting revenue and reputation.
Mitigating Factor: Lupin is working to resolve existing FDA warning letters and improve quality control processes across facilities.
Risk: Ongoing price erosion in the U.S. generic drug market.
Impact: Could squeeze profit margins and reduce overall profitability, especially for older products.
Mitigating Factor: Lupin is shifting focus to more complex generics and inhalation products which face less pricing pressure.
Risk: Volatility in currency exchange rates, especially for the U.S. dollar.
Impact: Volatility in currency exchange rates, especially for the U.S. dollar.
Mitigating Factor: Can negatively affect profitability of international operations and value of foreign currency debt.
CATALYSTS FOR GROWTH
Lupin's U.S. sales grew by 33.8% in FY2024 compared to the previous year, reaching INR 72,462 million. The U.S. now accounts for 37% of Lupin's global sales. Continued momentum in this key market, especially from inhalation products, could be a major driver for the stock.
Lupin's EBITDA margin improved significantly from 11.5% in FY2023 to 20% in FY2024. Further margin expansion through cost optimization and a more favorable product mix could boost profitability and the stock price.
Lupin has a robust pipeline of new products, especially in complex generics. Successful launches of high-value products, particularly in inhalation and injectables, could drive revenue growth and investor enthusiasm.
Disclaimer: The information provided in this newsletter is for educational and informational purposes only and does not constitute financial, investment, or legal advice. The content is solely the opinion of the author, who is not a qualified financial advisor, investment professional, or legal expert. All investments involve risk, and past performance does not guarantee future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions. The author of this newsletter is not liable for any losses or damages arising from the use of the information provided. This newsletter is not intended for distribution to, or use by, any person in any jurisdiction where such distribution or use would be contrary to local law or regulation.
Reply